Polaryx Therapeutics Inc.
PLYX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PLYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PLYX
Polaryx Therapeutics Inc. (PLYX) is a clinical-stage biopharmaceutical company focused on developing therapies for lysosomal storage disorders, with its lead candidate PLX-200 currently in Phase 2 trials. As of June 30, 2026, the company held $11.5 million in cash and equivalents, with an accumulated deficit of $103.6 million, and expects its cash runway to extend beyond the first quarter of 2027.
Key risk: Single-product dependency
BioSniper Score
Based on 6 of 6 signals
Market Cap
$97.5M
Cash Runway
25.5 moLead Asset
plx-100 (Phase 3)
Next Catalyst
Phase2_Start · Dec 1, 2026Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 2 clinical trials · 2 catalysts for Polaryx Therapeutics Inc..
Polaryx Therapeutics Inc. (PLYX) is a clinical-stage biopharmaceutical company focused on developing therapies for lysosomal storage disorders, with its lead candidate PLX-200 currently in Phase 2 trials. As of June 30, 2026, the company held $11.5 million in cash and equivalents, with an accumulated deficit of $103.6 million, and expects its cash runway to extend beyond the first quarter of 2027.
- Lead drug candidate PLX-200 is in Phase 2 development for a lysosomal storage disorder; a Phase 3 topline readout is expected by December 31, 2026 [sec_mda · as of 2026-08-13].
- Cash and equivalents totaled $11.5 million as of June 30, 2026, with net income of -$1.4 million for the quarter [sec].
- Accumulated deficit reached approximately $103.6 million as of June 30, 2026 [sec_mda · as of 2026-08-13].
- The company expects its current capital to fund operations beyond the first quarter of 2027 [sec_mda · as of 2026-08-13].
- Polaryx is substantially dependent on the success of PLX-200, and its future funding requirements will depend on clinical trial progress, manufacturing costs, and regulatory milestones [sec · filed 2025-11-21].
What works
- Polaryx has a defined clinical catalyst: a Phase 2 start for its lysosomal program on December 1, 2026, and a Phase 3 topline readout for PLX-200 by December 31, 2026 [upcoming catalysts].
- The company has advanced PLX-200 into Phase 2 trials, indicating progress in its lead program [sec · filed 2025-11-21].
- Management estimates current cash resources will support operations beyond the first quarter of 2027, providing a near-term development runway [sec_mda · as of 2026-08-13].
What to weigh
- Polaryx has an accumulated deficit of $103.6 million as of June 30, 2026, with no approved products or revenue sources [sec_mda · as of 2026-08-13].
- The company is substantially dependent on the success of a single drug candidate, PLX-200, and its clinical trials may not be successful [sec · filed 2025-11-21].
- Cash of $11.5 million is limited for a clinical-stage company, and future funding will be needed to complete development and commercialization [sec_mda · as of 2026-08-13].
- The company expects to continue incurring significantly increased expenses for the foreseeable future, which will pressure its capital resources [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Polaryx is substantially dependent on the success of PLX-200.
“We are substantially dependent on the success of our most advanced drug candidate, PLX-200, and our clinical trials of PLX-200 may not be successful.”
SEC filings · November 21, 2025
Accumulated deficit as of June 30, 2026 was $103.6 million.
“As of June 30, 2026, we had an accumulated deficit of approximately $103.6 million.”
SEC MD&A · August 13, 2026
Cash runway is expected to extend beyond the first quarter of 2027.
“capital in connection with our cash needs for capital expenditures and working capital beyond the first quarter of 2027.”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2026-12-01 · Phase2_Start · lysosomal — Initiation of an open-label, multicenter Phase 2 study for a lysosomal storage disorder program.
- 2026-12-31 · Phase3_Topline · plx-200 — Topline results from a randomized, double-blind, placebo-controlled Phase 3 study of PLX-200.
Risks & what to watch (4)›
Key risks
- Single-product dependency — Polaryx is substantially dependent on PLX-200; failure of its trials could be material [sec · filed 2025-11-21].
- Limited cash runway — Cash of $11.5M as of June 30, 2026 may not be sufficient to complete development without additional funding [sec].
- No approved products or revenue — The company has no commercial products and expects to incur significant expenses for the foreseeable future [sec_mda · as of 2026-08-13].
- Clinical and regulatory uncertainty — PLX-200 requires additional clinical development and regulatory approvals, which are uncertain [sec · filed 2025-11-21].
What to watch
- Phase 2 start for the lysosomal program on December 1, 2026 [upcoming catalysts].
- Phase 3 topline data for PLX-200 expected by December 31, 2026 [upcoming catalysts].
- Cash position updates and any financing activities to extend runway beyond Q1 2027 [sec_mda · as of 2026-08-13].
- Regulatory interactions and trial enrollment progress for PLX-200 [sec · filed 2025-11-21].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Polaryx Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Polaryx Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
25.5 months
D/E 0.08 · 0% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~93d
1 buy · 0 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$29.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 3,316,776 | $25.1M |
| geode capital management, llc | 170,673 | $1.3M |
| millennium management llc | 127,525 | $964K |
| vanguard fiduciary trust co | 104,556 | $790K |
| state street corp | 58,104 | $439K |
| blackrock, inc. | 41,012 | $310K |
| northern trust corp | 27,987 | $212K |
| bank of america corp /de/ | 25,881 | $196K |
| goldman sachs group inc | 13,483 | $102K |
| squarepoint ops llc | 12,406 | $94K |
Showing top 10 of 13 institutional holders of Polaryx Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 2.1%
- Days to cover
- 0.2
- Shares short
- 393,306
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PLYX short interestFrequently asked questions
What is the AI investment thesis for Polaryx Therapeutics Inc.?
Polaryx Therapeutics Inc. (PLYX) is a clinical-stage biopharmaceutical company focused on developing therapies for lysosomal storage disorders, with its lead candidate PLX-200 currently in Phase 2 trials. As of June 30, 2026, the company held $11.5 million in cash and equivalents, with an accumulated deficit of $103.6 million, and expects its cash runway to extend beyond the first quarter of 2027.
What is Polaryx Therapeutics Inc.'s lead drug candidate?
Polaryx Therapeutics Inc.'s most advanced tracked candidate is plx-100 (Phase 3) for LSDs (specifically CLN2).
What is Polaryx Therapeutics Inc.'s next catalyst?
Polaryx Therapeutics Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: An Open-Label, Multicenter, Phase 2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pr" — expected December 1, 2026.
Who is the CEO of Polaryx Therapeutics Inc.?
Mr. Alex Yang J.D., L.L.M. is the chief executive officer of Polaryx Therapeutics Inc. (PLYX).
Where is Polaryx Therapeutics Inc. headquartered?
Polaryx Therapeutics Inc. (PLYX) is headquartered in Paramus, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.